Miller-Meeks voted YEA on 100% of tracked bills classified as favoring Pharmaceuticals & Biotech, Securities & Investment, and Electric Utilities—the #7 highest rate among House members with sufficient votes in these sectors. She voted YEA on HR3537-117, classified as favoring Pharmaceuticals & Biotech to accelerate ALS therapies, while also voting YEA on 3 of 4 bills classified as limiting those same donor sectors.

EXAMPLE VOTES BEHIND THE NUMBER
HR3537-117 — Accelerating Access to Critical Therapies for ALS Act
HR8454-117 — Medical Marijuana and Cannabidiol Research Expansion Act
HJRES25-119 — Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule
FOLLOW THE TRAIL
◈ Ask the Analyst about Mariannette Miller-Meeks →How we built this: a statistical pattern surfaced from public records — FEC campaign finance, Senate/House Lobbying Disclosure Act filings, and Congress.gov. The donor concentration and the legislative action are concurrent facts; this does not imply contributions caused the action, that the member acted improperly, or that the bill specifically benefits the named sector. Generated August 2, 2026 · internal signal score 90/100.